NLRP3 and familial dilated cardiomyopathy: It has also been found that ticagrelor, a P2Y12 receptor antagonist, acts synergistically with dagliflozin to slow the progression of DCM by attenuating the activation of NLRP3 inflammatory vesicles via the AMPK/mTOR axis (132).